The activated AHR/ARNT complex (AHRC) regulates the expression of target genes upon exposure to environmental contaminants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Importantly, evidence has shown that TCDD represses estrogen receptor (ER) target gene activation through the AHRC. Our data indicates that AHR and ARNT act independently from each other at non-dioxin response element sites. Therefore, we sought to determine the specific functions of AHR and ARNT in estrogen-dependent signaling in human MCF7 breast cancer and human ECC-1 endometrial carcinoma cells. Knockdown of AHR with siRNA abrogates dioxin-inducible repression of estrogen-dependent gene transcription. Intriguingly, knockdown of ARNT does not effect TCDD-mediated repression of estrogen-regulated transcription, suggesting that AHR represses ER function independently of ARNT. This theory is supported by the ability of the selective AHR modulator 3′,4′-dimethoxy-α-naphthoflavone (DiMNF) to repress estrogen-inducible transcription. Furthermore, basal and estrogen-activated transcription of the genes encoding cathepsin-D and pS2 are down-regulated in MCF7 cells but up-regulated in ECC-1 cells in response to loss of ARNT. These responses are mirrored at the protein level with cathepsin-D. Furthermore, knock-down of ARNT led to opposite but corresponding changes in estrogen-stimulated proliferation in both MCF7 and ECC-1 cells. We have obtained experimental evidence demonstrating a dioxin-dependent repressor function for AHR and a dioxin-independent co-activator/co-repressor function for ARNT in estrogen signalling. These results provide us with further insight into the mechanisms of transcription factor crosstalk and putative therapeutic targets in estrogen-positive cancers.
Citation: Labrecque MP, Takhar MK, Hollingshead BD, Prefontaine GG, Perdew GH, Beischlag TV (2012) Distinct Roles for Aryl Hydrocarbon Receptor Nuclear Translocator and Ah Receptor in Estrogen-Mediated Signaling in Human Cancer Cell Lines. PLoS ONE 7(1): e29545. doi:10.1371/journal.pone.0029545
Editor: Bernhard Ryffel, French National Centre for Scientific Research, France
Received: October 24, 2011; Accepted: November 30, 2011; Published: January 3, 2012
Copyright: © 2012 Labrecque et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Canadian Breast Cancer Foundation - BC/Yukon, the Natural Sciences and Engineering Research Council to Dr. Beischlag, and a National Institutes of Health grant ES04869 to Dr. Perdew. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Elucidating the mechanisms underlying transcription is crucial to our understanding of how cells and organisms respond to physiological signals and environmental stimuli. The aryl hydrocarbon receptor (AHR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) are members of the basic helix-loop-helix/PER-ARNT-SIM (bHLH-PAS) family of proteins and form a heterodimeric transcription factor upon binding a variety of environmental contaminants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) . The activated AHR/ARNT complex (AHRC) plays key roles in carcinogenesis and regulates the expression of Cytochrome P4501A1 (CYP1A1) and other xenobiotic target genes to combat the effects of environmental contaminants . In addition, AHR has been shown to be important for normal development and physiological homeostasis , ,  and is essential for certain functions of the immune response, such as regulation of interleukin-17 producing T-helper cells  and induction of the cytokine interleukin-6 in MCF7 breast cancer cells .
Unliganded AHR exists in the cytoplasm as part of a multimeric complex containing two molecules of HSP90, the HSP90 co-chaperone p23, and hepatitis B virus X-associated protein 2 (XAP2) , , , . Upon ligand binding, AHR translocates to the nucleus where it associates with ARNT to form a functional transcription factor complex, the AHRC. As an activated complex, the AHRC is capable of recruiting regulatory proteins, such as steroid receptor coactivator-1 (SRC-1), CREB binding protein (CBP/p300), NCoA2/GRIP1 , , receptor-interacting-protein 140 (RIP140) , CoCoA , GAC63 , NcoA4  and TRIP230 , which play significant roles in determining the activity of TCDD-induced gene transcription. These co-activators and co-repressors incorporate themselves into multimeric complexes that modify chromatin structure, stabilize core transcriptional machinery, and mediate RNA chain elongation . In addition to these classic transcriptional co-activators and co-repressors, AHR is recruited by other transcription factors during transcription, including estrogen receptor-α (ERα) , ,  and NF-κB  to modify their intrinsic activities.
ERα/β are ligand activated transcription factors that belong to the superfamily of nuclear hormone receptors (NR)  and bind 17β-estradiol (E2) to regulate genes involved in reproduction and cellular growth and proliferation . Upon ligand binding, ER forms a functional homodimer and binds its cognate response elements. Interestingly, there is a ligand-dependent reciprocal disruption between ER and AHR signaling. For instance, activated ERα inhibits AHRC activity at CYP1A1 through direct protein-protein interactions, termed transrepression . Conversely, TCDD's anti-estrogenic properties are well documented as it represses the E2-inducible genes pS2 and cathepsin-D (CAT-D) , , . However, the mechanisms of repression occurring at E2-responsive genes are unclear. Proposed theories for this repression include: (i) competition for a common pool of co-activators ; (ii) a direct down-regulation of CAT-D transcription through upstream inhibitory dioxin response elements ; (iii) activation of a TCDD-inducible inhibitory factor ; (iv) an AHR-dependent E3-ligase that degrades proteins crucial for ER-signalling , or; (v) a direct transrepression interaction between AHR and ER , .
In this study, we examined the role of AHR and ARNT on ERα-dependent target gene transcription in the human MCF7 breast cancer and the human ECC-1 endometrial-cervical cancer cell lines. Our data suggest that AHR and ARNT act independently from each other at off-target sites and we revealed that ARNT is not essential for TCDD-dependent repression of ER-signaling. In addition, we have demonstrated that ARNT acts as a cell specific coactivator in MCF7 cells, and as a corepressor in ECC-1 cells. Finally, we show that ARNT knockdown not only affects accumulation of mRNA and protein of ERα-target genes, but also has phenotypic consequences by influencing ERα-mediated cell proliferation.
AHR-dependent repression of estrogen signaling in ECC-1 cells
The presence of AHR, ARNT and ERα at the dioxin-inducible CYP1A1 enhancer and the E2-inducible pS2 promoter has already been documented in MCF7 cells and other breast cancer cell lines , , ,  . Although preliminary studies have identified ECC-1 human endometrial cells as an ideal system to study dioxin disruption of estrogen signaling ,  very little is known concerning the roles of AHR, ARNT and ER and their respective interactions in this cell line. We employed the ChIP assay to ascertain the status of these proteins at the pS2 promoter and CYP1A1 enhancer in both the presence and absence of E2 and TCDD. ECC-1 cells were treated with DMSO, 10 nM E2, 2 nM TCDD or a combination of E2 and TCDD for 45 min. After chemically cross-linking protein to DNA with formaldehyde, cells were harvested and sonicated. Sheared DNA-protein complexes were precipitated with antibodies specific to AHR, ARNT or ERα and then isolated complexes were reverse-crosslinked and DNA was subjected to PCR amplification. Consistent with other investigators' observations in breast cancer cells, we observed the recruitment of AHR and ARNT on the human CYP1A1 enhancer in a TCDD-dependent fashion and ERα was greatly enriched only after treatment with a combination of 2 nM TCDD and 10 nM E2 (Figure 1A). Furthermore, the recruitment of ERα to the pS2 promoter occurs in an E2-dependent fashion while AHR and ARNT are present after treatment with either ligand but are enriched during co-treatment (Figure 1B).
Chromatin immunoprecipitation assays of the CYP1A1 enhancer (A) and pS2 promoter (B) regions in ECC-1 cells using antibodies targeting AHR, ARNT or ERα. Cells were treated for 45 min with either DMSO, E2 (10 nM), TCDD (2 nM) or a combination of E2 and TCDD. (C and D) The functional role of AHR in TCDD-mediated transcription. ECC-1 cells were transfected with siRNAs to either GFP (siGFP) as a negative control or AHR (siAHR#3 or siAHR#4) 24 h prior to ligand treatment, then cells were treated with DMSO, E2 (10 nM), TCDD (2 nM) or a combination of E2 and TCDD. The mRNA levels for pS2 (C) and CYP1A1 (D) were determined through real-time RT-PCR and normalized to constitutively active GAPDH expression. (E) ECC-1 cells were transfected with siRNA's to AHR and harvested for whole cell lysates for Western Blot analysis of AHR, ERα and XAP2 protein levels.
We have previously shown that ERα associates with the AHRC to mediate estradiol-dependent transrepression of dioxin-inducible gene transcription . Therefore, we set out to determine the functional significance of AHR in estrogen-inducible gene transcription. We transfected ECC-1 cells with small inhibitory RNA directed towards either AHR (siAHR) or a GFP negative control (siGFP). After transfection, cells were serum starved for 24 h, followed by 24 h ligand treatment and then harvested for total mRNA that was quantified through quantitative PCR. As expected, ablation of AHR and co-treatment with 2 nM TCDD and 10 nM E2 results in the loss of TCDD-induced repression of pS2 transcription (Figure 1C). However, loss of AHR had no measurable effect on basal, or estrogen activated pS2 mRNA accumulation. As a control for siRNA specificity, Western blots of AHR protein show a greatly reduced expression of AHR protein after transfection and unchanged protein levels of ERα and XAP2 which served as a loading control (Figure 1E). These demonstrate the specificity of the siRNA's to AHR, and that loss of AHR does not affect accumulation or turnover of basal ERα protein levels. Furthermore, the induction of CYP1A1 transcription with TCDD after AHR knockdown is attenuated when compared to the siGFP negative control (Figure 1D). Thus, AHR is a requirement for TCDD-induced repression of E2-responsive gene transcription and the increased transcriptional response with combinatorial treatment is due solely to the loss of AHR and other putative transcriptional modifiers associated with its presence. Finally, we obtained essentially identical results in both MCF7 and ECC-1 cell lines under serum-starved or charcoal-stripped serum conditions suggesting that differences in the cell lines' ability to go through cell cycle does not impact this phenomenon. Together, these results support the concept that the ECC-1 cell line is an excellent alternative cell model to study dioxin-induced disruption of estrogen receptor signaling.
ARNT has cell specific co-activator/co-repressor functions
The identification of ARNT as a co-activator in estrogen signalling , , juxtaposed with the known transrepressor effects of TCDD, led us to investigate the role played by ARNT in TCDD-mediated transrepression of ER function in various human cancer cell lines, namely MCF7 and ECC-1 cells. Through siRNA directed towards ARNT and a scrambled negative control (siSCX), and subsequent qPCR analysis of endogenous pS2 and CAT-D gene transcription, we made several interesting observations. First, ARNT displays co-repressor properties in ECC-1 cells. Accumulation of pS2 (Figure 2A) and CAT-D (Figure 2B) mRNA levels are exacerbated during E2 treatments after loss of ARNT suggesting a cell specific function for ARNT independent of AHR. Furthermore, we observed this phenomena with three separate siRNAs directed towards ARNT (siRNA's 1 and 3 are shown in Figure 2A, B and C). We used at least two siRNA's for all other experimental parameters with essentially identical results, but for brevity, hereafter we only present data depicting the use of one siRNA. Secondly, consistent with the findings of several other investigators, ARNT displayed co-activator properties in MCF7 cells , . Indeed, knockdown of ARNT protein dampens E2-induced transcription of pS2 (Figure 2C) and CAT-D (Figure 2D). Finally, in a dose response experiment, we observed a concomitant decrease of CAT-D protein levels with increasing concentrations of TCDD in both ECC-1 and MCF7 cells (Figure 2E). These data indicate that ARNT function as it relates to ER signaling is likely dictated by other factors specific to the cellular environment.
ECC-1 cells (A and B) and MCF7 cells (C and D) were transfected with either scrambled siRNA (siSCX) or siRNA directed to ARNT (siARNT#1 or siARNT#3). Twenty-four hours after transfection, cells were treated with vehicle (DMSO), E2 (10 nM), TCDD (2 nM) or a combination of E2 and TCDD. Gene expression was determined by real-time RT-PCR after isolation and reverse transcription of total RNA. CAT-D and pS2 expression were normalized to constitutively active 36B4 gene expression. (E) Western blot analysis of CAT-D protein levels in MCF7 and ECC-1 cells. Cells were treated with DMSO or E2 (10 nM) and varying concentrations of TCDD (10 pM, 50 pM, 100 pM, 500 pM, 1 nM or 5 nM). After 24 hours of treatment, whole cell lysates were harvested, and Western Blot assays were performed using antibodies directed against CAT-D and α-tubulin. Error bars represent ± S.D. * p<0.05.
To determine if the modulation of transcriptional activity translated into similar protein expression profiles, we used Western blot analysis to visualize the level of CAT-D protein after ARNT knockdown. Cells were transfected and ligand treated under identical conditions as the qPCR parameters. When compared to the scrambled negative control, CAT-D protein expression after E2 treatment is exacerbated in ECC-1 cells with ARNT knockdown (Figure 3A). Conversely, MCF7 cells transfected with ARNT siRNA resulted in a blunted expression of CAT-D protein during E2 treatment (Figure 3C). Furthermore, ERα levels remained consistent, regardless of ARNT status (Figure 3A and C). Most importantly, dioxin-induced repression of ER signaling was maintained at the protein level after ARNT knockdown (Figure 3A and C). The representative blots were normalized to α-tubulin and luminescence was measured using GeneTools 4.01.2 software (Syngene). These normalized values showed a two-fold induction of CAT-D in ECC-1 cells with ARNT knockdown after E2 treatment (Figure 3B, columns 2 and 6), whereas in MCF7 cells, knock-down of ARNT resulted in a 40% decrease in E2-dependent CAT-D expression (Figure 3D, colunms 2 and 6). These results provide concrete evidence that the level of protein expression mirrors the transcriptional response in both cell lines and that physiological consequences must ensue with loss of ARNT.
ECC-1 (A and B) and MCF7 (C and D) cells were transfected with either siSCX or siARNT and ligand treated as described in Figure 2. (A and C) Representative Western blots of ARNT, CAT-D, ERα and α-tubulin protein levels. Bar graphs of CAT-D protein levels in ECC-1 (B) and MCF7 (D) cells after normalizing luminescence values to α-tubulin. Open bars represent ligand treatments after siRNA to scrambled negative control (siSCX) and closed (black) bars represent ligand treatments after siRNA to ARNT (siARNT). Experiments were performed three times with essentially identical outcomes.
These surprising results were coupled with the observation that TCDD-induced repression of ER-signaling is maintained in both cell lines after ARNT knockdown (Figure 2 and 3) thus providing evidence that ARNT is not required for TCDD/AHR-dependent repression of ERα signaling. This hypothesis is supported by the ability of a selective aryl hydrocarbon receptor modulator (SAHRM) to repress estrogen signaling. We examined the ability of the known SAHRM, DiMNF ,  to repress E2-mediated transcription by RT-PCR in MCF7 and ECC-1 cells (Figure 4). DiMNF was as effective at repressing CAT-D mRNA accumulation as TCDD. DiMNF is a potent antagonist of AHR and effectively displaces TCDD from the receptor at 1 µM . In addition, DiMNF fails to induce AHR-ARNT-dioxin response element formation in an electrophoretic mobility shift assay, suggesting that AHR-ARNT dimerization may not occur , thus, it seems likely that AHR's transrepression function is entirely ARNT-independent.
The effect of 1 µM DiMNF on E2-inducible CAT-D expression in MCF7 and ECC-1 cells. Cells were treated with the indicated ligands for 24 h prior to RNA isolation. Gene expression was determined as described above. Error bars represent ± S.D. * p<0.05.
ARNT knockdown causes increased proliferation in ECC-1 cells and decreased proliferation in MCF7 cells
Sensitivity to estrogen has been linked to proliferation and cell transformation in ER-positive carcinoma cells . To establish if ARNT can influence E2-dependent cellular proliferation, we performed proliferation assays on ECC-1 and MCF7 cells after ARNT siRNA treatment. Consistent with our quantitative PCR and Western blot data, ECC1 and MCF7 cells displayed altered rates of proliferation after ARNT knockdown compared to cells transfected with the scrambled negative control siRNA (Figure 5A and B). Knockdown of ARNT was monitored for 72 h and the significant knock-down observed was unchanged essentially at each time point (Figure 5C). Neither cell line displayed altered growth patterns until the 48 hour time point. At 48 hours, ECC-1 cells in both the siSCX and siARNT conditions showed modest proliferation in response to E2 treatments. At the 96 hour time point, there was a highly significant increase in E2-inducible proliferation of ECC-1 cells treated with siARNT, compared to scrambled control treated cells. Intriguingly, ARNT knockdown increased basal growth rates and caused an exacerbated response to E2 with the cell number nearly doubling in the siARNT E2 treatments compared to the siSCX E2 treatments. Conversely, MCF7 cells showed a decreased proliferation rate after ARNT knockdown (Figure 5B). The growth rates were not significantly different until the 48 h time point, when the E2-inducible proliferative response in the scrambled negative control was apparent. The siARNT transfected cells had a blunted growth response during both control and E2 conditions. At 96 hours, the cells began losing sensitivity to E2 and entered into a senescent state. Whether or not this was due to the growth conditions is unclear. However, these data further support the hypothesis that ARNT has co-repressor properties in ECC-1 cells and co-activator properties in MCF7 cells. Moreover, the sensitivity to E2 and the reciprocal growth responses exhibited by the two cell lines are bona fide phenotypic consequences of ARNT ablation.
ECC-1 (A) and MCF7 (B) cells were transfected with either siSCX or siARNT for 6 hours, then trypsinized and reseeded at 10,000 cells/well in 12-well dishes. Twenty-four hours after seeding, cells were treated with either DMSO or E2 (10 nM) and cell counts were conducted at 0, 48 and 96 hours after treatments with a Fuchs-Rosenthal Counting Chamber. At the 48 h time point, cells were treated a second time with 10 nM E2. Experiments were done in triplicate and each trial was counted three times. (C) Western blot analysis of ARNT after siRNA knock-down reveals that significant knock-down was achieved and persists over a 72 h period. Error bars represent ± S.D. * p<0.05.
Many environmental contaminants that serve as activators of the aryl hydrocarbon receptor are known as putative endocrine disrupting compounds. Exposure to many of these compounds occur on a daily basis and represents significant risks to human health. In particular, the repressive effects elicited by ligands of the AHR on ER signaling have been well documented , , , , . Other reports have described the co-activator potential of ARNT for ER-mediated transcription . Despite the growing body of evidence to support roles for AHR and ARNT in ER function, little is known about the normal physiological role of these proteins as they relate to estrogen signaling or the molecular determinants of toxicant-induced transrepression of ER function by AHR. Finally, this investigation revealed that ARNT is not essential for AHR-mediated off-target transrepression. In order to delineate the molecular mechanisms underlying AHR-mediated transrepression we sought to uncouple AHR and ARNT function in ER-positive human cancer cell lines. In doing so, we discovered that ARNT attenuates activated ER-target gene transcription in ECC-1 cells, in direct contrast to its co-activator function described in MCF7 cells .
ARNT was originally identified as a bona fide transcription factor  and dimerization partner of AHR . Beyond its canonical transcription factor function, ARNT can interact with several other transcription factors, including ERα  and its co-activator function for ER signaling has been well described , . Therefore, we expected that knockdown of ARNT in ECC-1 endometrial-cervical cancer cells would result in a diminution of ER target gene expression. The resulting increase in mRNA accumulation, protein expression and E2-inducible proliferation strongly suggests that ARNT acts as a transcriptional co-repressor in this cell line. The molecular mechanism(s) underlying the differences observed in MCF7 and ECC-1 cells likely is related to differences in the nature and composition of the ancillary transcriptional machinery recruited by ARNT in each cell line. ARNT presents several different protein-protein interaction domains for the recruitment of co-activator proteins, including a carboxy-terminal transactivation domain , its PAS-B region  and its basic-helix-loop-helix domain . In addition, an association between ARNT and the transcriptional co-repressor protein, SMRT has been demonstrated . However, we believe that this is the first demonstration that ARNT has dual co-activator/co-repressor functions in a cell-specific fashion (Figure 6). In addition, the repercussions of these transcriptional effects can be observed at the translational and phenotypic levels.
The presence of E2 facilitates the assembly of transcriptional modifiers that induce transcription of E2-responsive genes. Ligand activated AHR represses ER-signaling independent of ARNT. The loss of ARNT in ECC-1 cells, where it acts as a co-repressor, leads to increased sensitivity to E2 and increased transcriptional activity at ER regulated genes. The loss of ARNT in MCF7 cells, where it acts as a co-activator, leads to decreased sensitivity to E2 and decreases transcriptional activity at ER regulated genes.
Several models have been hypothesized to explain the molecular mechanisms underlying transcription factor mediated cross-talk, particularly the ability of one transcription factor to repress another's function . Reugg and colleagues, among others, have suggested that transcription factor-mediated transrepression might be the result of competition for a limited pool of co-activator proteins . However, the identification of ARNT as a co-repressor in ECC-1 cells unmasks a more complex mechanism of transrepression at E2-inducible genes then the co-activator competition model suggests. While these data do not definitively disprove this model, we believe that our data suggest that it is unlikely because co-activator competition cannot account for TCDD-inducible repression in ECC-1 cells as activated AHR should squelch ARNT's co-repressor function. In addition, ARNT, a protein that has demonstrated the ability to recruit numerous co-activators , , , , ,  should illicit an effect similar to ligand-activated AHR if co-activator pools were in such limited supply that competition would hinder individual transcription factor function. This clearly is not the case in the ECC-1 cell line.
The experimental evidence presented above indicates that AHR does not require ARNT to mediate its off-target transrepressor effects. Loss of ARNT in both MCF7 and ECC-1 cells failed to abrogate the repressive effects of TCDD on E2-inducible transcription and protein expression (Figures 2 and 3). The effects DiMNF-bound AHR are independent of dioxin response element binding as nuclear extract from cells treated with DiMNF does not retard the movement of a labeled dioxin response element probe in gel shift assays . Furthermore, AHR-ARNT dimerization is a requirement for DNA binding, suggesting that this may not occur in the presence of DiMNF. This represents a paradigm shift in our understanding of AHR function and has implications for the use and effectiveness of selective AHR modulators. Indeed, a novel AHR antagonist has proven to be a potent stimulator of AHR-dependent stem cell expansion . Thus, antagonists that do not elicit AHR-ARNT dimerization might be more effective repressors of ER function than pure agonists as AHR would not be squelched by ARNT binding. The SARHM DiMNF is a potent AHR-dependent repressor of cytokine signaling , . Furthermore, DiMNF was effective in repressing ER-regulated target gene expression (Figure 4). Molecular modelling studies demonstrate that DiMNF forms an extra hydrogen bond with AHR at Thr289 , a characteristic not shared with the partial agonist α-naphthoflavone suggesting that the DiMNF-AHR adopts a unique confirmation. Thus, the flavonoids represent a class of compounds that may be attractive targets for further testing and development to determine their effects on ER target gene expression.
Our experimental evidence demonstrates a TCDD-dependent repressor function for AHR and a TCDD/AHR-independent co-activator/co-repressor function for ARNT in estrogen signaling. These results provide us with further insight into the mechanisms of transcription factor crosstalk and putative therapeutic targets in estrogen-positive cancers. Taken together, our data suggest a more complex mechanism of ARNT function and AHR-mediated transrepression of ER-signaling than previously suggested. The clinical utility of these findings remains to be tested and will be the subject of future investigations.
Materials and Methods
Materials and Cell culture
3′,4′-dimethoxy-α-naphthoflavone (DiMNF) was obtained commercially (Indofine Chemical Co., Hillsborough, NJ). ECC-1 and MCF7 cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium (DMEM; BioWhittaker, Lonza,) with 10% fetal bovine serum (FBS; HyClone, PerBio, Thermo Fisher Scientific Inc.) and supplemented with 100 units/ml potassium penicillin-100 µg/ml streptomycin sulphate (BioWhittaker, Lonza) at 37°C, 20% O2, and 5% CO2. Twenty-four h before any experimental perturbation, cells were washed 2× with PBS, and maintained in Phenol-Red-free media without FBS .
Chromatin immunoprecipitation assays.
Chromatin immunoprecipitation (ChIP) assays were performed as described by previously . Briefly, cells were plated into 150 cm2 dishes and serum-starved 24 h before treatment. Treatment of cells was done in serum-free media supplemented with 3 mg/mL bovine serum albumin for 45 min. Chromatin complexes were chemically cross-linked using a 1% formaldehyde/0.7 mol/L HEPES solution (final concentration), pH 7.8, and complexes were sonicated to yield DNA fragments of 200 to 900 bp size. Complexes were precleared with protein A agarose resin (CalBiochem) and incubated overnight with specific antibodies [ERα rabbit polyclonal or ARNT goat polyclonal (Santa Cruz) or AHR rabbit polyclonal described previously . Immunoadsorbed complexes were captured on protein A agarose resin and washed twice with 0.5× RIPA, followed by three washes with 10 mmol/L Tris-HCl (pH 8.0) and 1 mmol/L EDTA. Samples were eluted off of the resin using 100 mmol/L NaHCO3 and 1% SDS, and cross-links were reversed at 65°C overnight. Samples were phenol-chloroform extracted and precipitated with 70% EtOH and Pellet Paint (Novagen). Immuno-adsorbed DNA was analyzed by PCR. Primers for the CYP1A1 enhancer and pS2 promoter have been described previously , .
MCF7 and ECC-1 cells were cultured in the conditions described above until approximately 70% confluent before siRNA transfection. Cells were transfected with either Green Fluorescence Protein (GFP) siRNA (Dharmacon), scrambled (SCX) siRNA (DS Scrambled negative control siRNA, Integrated DNA Technologies Inc.), AHR siRNAs (Dharmacon) or ARNT siRNAs (Integrated DNA Technologies Inc., Cat. No. HSC.RNAI.N187426.11.1, HSC.RNAI.N178426.11.2, HSC.RNAI.N178426.11.3; siARNT 1, siARNT 2, and siARNT 3 respectively). Cells were transfected with 10–15 nM siRNA using 0.3% (v/v) Trifectin (Integrated DNA Technologies) according to manufacturer's protocol. The cells were allowed to incubate in transfection mix for 6 h at 37°C, and 5% CO2 after which the transfection mix was removed and replaced with serum free medium.
Reverse transcription and Real-Time PCR
Reverse transcription and real-time PCR were performed as described previously . In brief, cells were treated either with DMSO (Me2SO), TCDD (2 nM), E2 (10 nM), or a combination of TCDD and E2, for 24 h. For studies involving the selective AHR modulator 1 µM 3′,4′-dimethoxy-α-naphthoflavone (DiMNF) with either DMSO, E2 (10 nM), diMNF (1 µM) or E2 and diMNF in combination. Cells were harvested in TRI Reagent (Sigma) and total RNA was isolated and subjected to reverse transcription using a High Capacity cDNA Archive kit (Applied Biosystems). Complimentary DNA was amplified by real-time PCR using a Power SYBR Green PCR kit (Applied Biosystems) according to manufacturer's protocols. Oligonucleotide pairs used to amplify human cDNA sequences were described previously . DNA was amplified for 45 cycles in a StepOne Plus Real-Time PCR System (Applied Biosystems).
Western blot analysis
In order to determine the effects of TCDD on E2-inducible protein levels, MCF7 and ECC-1 cells were treated either with vehicle (Me2SO), TCDD (2 nM), E2 (10 nM), or a combination of TCDD and E2 for 24 h. For protein analysis that included siRNA treatment, cells were transfected for 6 h and then starved in serum free media for 24 h prior to ligand treatments. Cells were harvested and the protein concentration determined by the RC DC protein assay (Bio-Rad). Equal amounts of proteins from the samples were resolved on a SDS-acrylamide gel then transferred to polyvinylidene fluoride (PVDF) membrane. Upon completion of transfer, the membrane was wetted with 100% methanol then probed with anti-ARNT (goat polyclonal IgG; Santa Cruz Biotechnology, Inc.), anti-AHR (rabbit polyclonal, Biomol, GmbH), anti-CAT-D (rabbit polyclonal IgG; Santa Cruz Biotechnology, Inc.), anti-ERα (rabbit polyclonal IgG; Santa Cruz Biotechnology, Inc.), anti-α-tubulin (mouse monoclonal IgG; Santa Cruz Biotechnology, Inc.) or anti-XAP2 mouse monoclonal antibody. The detection was performed using horseradish peroxidase conjugated anti-mouse or anti-rabbit or anti-goat IgG and ECL detection kit (GE Healthcare).
MCF7 cells and ECC-1 cells at 75–80% confluency were transfected with either ARNT or scrambled negative control siRNA. After 6 h, cells were washed 2 times with PBS, trypsinized and seeded into 12-well plates at 10,000 cells/well in DMEM with 2.5% charcoal-stripped FBS. Twenty-four hours after plating, E2 was added directly to half the wells to a final concentration of 10 nM. Cells were counted at; 0 (control), 12, 24, 48 and 96 h following E2 administration. A second treatment of E2 (10 nM) was added to the cells at 48 hrs. Determinations were performed in triplicate and each sample was counted three times.
Statistical analyses were performed using GraphPad Prism 4.0. For multiple comparisons (i.e. siRNA experiments) statistical significance was determined using a 2-way ANOVA with Tukey's Multiple Comparison test. Values are presented as means ± standard error of the mean (SEM). A P value<0.05 was considered to be significant.
Conceived and designed the experiments: TVB GHP GGP. Performed the experiments: MPL MKT BDH. Analyzed the data: TVB MPL GGP. Contributed reagents/materials/analysis tools: TVB GHP GGP. Wrote the paper: MPL TVB GGP GHP BDH.
- 1. Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35: 307–340.
- 2. Elizondo G, Fernandez-Salguero P, Sheikh MS, Kim GY, Fornace AJ, et al. (2000) Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol Pharmacol 57: 1056–1063.
- 3. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, et al. (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268: 722–726.
- 4. Alexander DL, Ganem LG, Fernandez-Salguero P, Gonzalez F, Jefcoate CR (1998) Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J Cell Sci 111(Pt 22): 3311–3322.
- 5. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2008) Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A 105: 9721–9726.
- 6. Hollingshead BD, Beischlag TV, Dinatale BC, Ramadoss P, Perdew GH (2008) Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. Cancer Res 68: 3609–3617.
- 7. Carver LA, Bradfield CA (1997) Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J Biol Chem 272: 11452–11456.
- 8. Kazlauskas A, Poellinger L, Pongratz I (1999) Evidence that the co-chaperone p23 regulates ligand responsiveness of the dioxin (Aryl hydrocarbon) receptor. J Biol Chem 274: 13519–13524.
- 9. Ma Q, Whitlock JP Jr (1997) A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Chem 272: 8878–8884.
- 10. Pongratz I, Mason GG, Poellinger L (1992) Dual roles of the 90-kDa heat shock protein hsp90 in modulating functional activities of the dioxin receptor. Evidence that the dioxin receptor functionally belongs to a subclass of nuclear receptors which require hsp90 both for ligand binding activity and repression of intrinsic DNA binding activity. J Biol Chem 267: 13728–13734.
- 11. Beischlag TV, Perdew GH (2005) ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem 280: 21607–21611.
- 12. Beischlag TV, Wang S, Rose DW, Torchia J, Reisz-Porszasz S, et al. (2002) Recruitment of the NCoA/SRC-1/p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Mol Cell Biol 22: 4319–4333.
- 13. Kumar MB, Perdew GH (1999) Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. Gene Expr 8: 273–286.
- 14. Kim JH, Stallcup MR (2004) Role of the coiled-coil coactivator (CoCoA) in aryl hydrocarbon receptor-mediated transcription. J Biol Chem 279: 49842–49848.
- 15. Chen YH, Beischlag TV, Kim JH, Perdew GH, Stallcup MR (2006) Role of GAC63 in transcriptional activation mediated by the aryl hydrocarbon receptor. J Biol Chem 281: 12242–12247.
- 16. Kollara A, Brown TJ (2006) Functional interaction of nuclear receptor coactivator 4 with aryl hydrocarbon receptor. Biochem Biophys Res Commun 346: 526–534.
- 17. Beischlag TV, Taylor RT, Rose DW, Yoon D, Chen Y, et al. (2004) Recruitment of thyroid hormone receptor/retinoblastoma-interacting protein 230 by the aryl hydrocarbon receptor nuclear translocator is required for the transcriptional response to both dioxin and hypoxia. J Biol Chem 279: 54620–54628.
- 18. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr 18: 207–250.
- 19. Matthews J, Wihlen B, Thomsen J, Gustafsson JA (2005) Aryl Hydrocarbon Receptor-Mediated Transcription: Ligand-Dependent Recruitment of Estrogen Receptor α to 2,3,7,8-Tetrachlorodibenzo- p-Dioxin-Responsive Promoters. Mol Cell Biol 25: 5317–5328.
- 20. Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, et al. (2003) Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature 423: 545–550.
- 21. Tian Y, Ke S, Denison MS, Rabson AB, Gallo MA (1999) Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J Biol Chem 274: 510–515.
- 22. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835–839.
- 23. Acconcia F, Kumar R (2006) Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238: 1–14.
- 24. Biegel L, Safe S (1990) Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52- and 160-kDa proteins in human breast cancer cells. J Steroid Biochem Mol Biol 37: 725–732.
- 25. Kharat I, Saatcioglu F (1996) Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor. Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem 271: 10533–10537.
- 26. Zacharewski TR, Bondy KL, McDonell P, Wu ZF (1994) Antiestrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 beta-estradiol-induced pS2 expression. Cancer Res 54: 2707–2713.
- 27. Ruegg J, Swedenborg E, Wahlstrom D, Escande A, Balaguer P, et al. (2008) The transcription factor aryl hydrocarbon receptor nuclear translocator functions as an estrogen receptor beta-selective coactivator, and its recruitment to alternative pathways mediates antiestrogenic effects of dioxin. Mol Endocrinol 22: 304–316.
- 28. Safe S, Wormke M, Samudio I (2000) Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol Neoplasia 5: 295–306.
- 29. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, et al. (2007) Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446: 562–566.
- 30. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, et al. (2003) The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci U S A 100: 6517–6522.
- 31. Castro-Rivera E, Wormke M, Safe S (1999) Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells. Mol Cell Endocrinol 150: 11–21.
- 32. Ricci MS, Toscano DG, Toscano WA Jr (1999) ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function. In Vitro Cell Dev Biol Anim 35: 183–189.
- 33. Murray IA, Krishnegowda G, DiNatale BC, Flaveny C, Chiaro C, et al. (2010) Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chem Res Toxicol 23: 955–966.
- 34. Murray IA, Flaveny CA, Chiaro CR, Sharma AK, Tanos RS, et al. (2011) Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′,4′-dimethoxy-alpha-naphthoflavone. Mol Pharmacol 79: 508–519.
- 35. Vendrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, et al. (2004) Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol 32: 397–414.
- 36. Astroff B, Rowlands C, Dickerson R, Safe S (1990) 2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibition of 17 beta-estradiol-induced increases in rat uterine epidermal growth factor receptor binding activity and gene expression. Mol Cell Endocrinol 72: 247–252.
- 37. Astroff B, Safe S (1988) Comparative antiestrogenic activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 6-methyl-1,3,8-trichlorodibenzofuran in the female rat. Toxicol Appl Pharmacol 95: 435–443.
- 38. Gallo MA, Hesse EJ, Macdonald GJ, Umbreit TH (1986) Interactive effects of estradiol and 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic cytochrome P-450 and mouse uterus. Toxicol Lett 32: 123–132.
- 39. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, et al. (1991) Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252: 954–958.
- 40. Reyes H, Reisz-Porszasz S, Hankinson O (1992) Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256: 1193–1195.
- 41. Partch CL, Gardner KH (2011) Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proc Natl Acad Sci U S A 108: 7739–7744.
- 42. Nguyen TA, Hoivik D, Lee JE, Safe S (1999) Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. Arch Biochem Biophys 367: 250–257.
- 43. Partch CL, Card PB, Amezcua CA, Gardner KH (2009) Molecular basis of coiled coil coactivator recruitment by the aryl hydrocarbon receptor nuclear translocator (ARNT). J Biol Chem 284: 15184–15192.
- 44. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, et al. (1996) An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 93: 12969–12973.
- 45. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, et al. (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329: 1345–1348.
- 46. Perdew GH, Hollingshead BD, Dinatale BC, Morales JL, Labrecque MP, et al. (2010) Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity. J Pharmacol Exp Ther 335: 273–283.
- 47. DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH (2010) Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling. J Biol Chem 285: 24388–24397.
- 48. Hestermann EV, Brown M (2003) Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol 23: 7920–7925.